Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.
about
Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapyDifferent dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapyAcute lymphoblastic leukaemiaL-asparaginase in the treatment of patients with acute lymphoblastic leukemiaBest Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on AsparaginaseDevelopment of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemiaAsparaginase pharmacokinetics and implications of therapeutic drug monitoringHow to manage asparaginase hypersensitivity in acute lymphoblastic leukemiaCrystal structure of active site mutant of antileukemic L-asparaginase reveals conserved zinc-binding sitePolymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemiaModeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cellsBreastfeeding as a Protective Effect Against Childhood Leukemia and LymphomaHLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and MarComparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia.Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia.Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407Conservative management of pancreatic pseudocysts in children with acute lymphoblastic leukemiaBeneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis.Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemiaEvaluation for inherited and acquired prothrombotic defects predisposing to symptomatic thromboembolism in children with acute lymphoblastic leukemia: a protocol for a prospective, observational, cohort study.Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000).TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trialIntravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia.Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumorsThe glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells.Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trialHematopoietic stem cell transplantation for leukemiaSuccessful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginaseDexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment.Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemiaDo children with central venous line (CVL) dysfunction have increased risk of symptomatic thromboembolism compared to those without CVL-dysfunction, while on cancer therapy?L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginaseThe toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.Cellular context-dependent effects of H2ax and p53 deletion on the development of thymic lymphoma.Comprehensive cancer centres and the war on cancer.Outcome of Adolescents with Acute Lymphoblastic Leukemia Treated by Pediatrics versus Adults ProtocolsPolymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia.
P2860
Q24240568-8D1F5A61-FB13-435D-BBFF-D6A3259622C8Q24243810-56412D9D-3AE0-4F13-A702-8F42CA7EE189Q24602387-65700FE8-87CC-48AE-8413-FE9722F5C2F2Q26738640-8707B613-06D5-4430-8E48-5F4D32D3E926Q26784116-3B295464-2AC7-4D5C-9B8B-611D226E6BDCQ26825970-E5C67E6B-CD22-46CA-A18D-C05992D0DFD3Q27026476-C6FA35B9-4E50-4655-8D38-07B9242D79CBQ27026952-0992B598-99A9-4271-91B4-E842C31758FAQ27694569-FB8068B2-D052-42FC-A065-477BBC358343Q28245060-659AF494-44FD-434F-B538-8AE3D64682A8Q28476416-13EB8437-C1E3-4754-9165-03DA2FA0DBFCQ28818624-D29B5D74-753B-44B8-A0D2-02770E9D7EBBQ30371340-504EBA28-7981-4ADE-B17B-B1D005CF293AQ30444738-8786CFCA-7805-4777-93F7-949BD6A0497DQ30457370-F2C7E575-2998-42BF-A3D6-EE7B87339F5CQ33395469-6C0214E4-5584-44F8-8053-34B73A016AA6Q33557148-F2B48919-9766-4352-9217-8FC8EA64C61AQ33559419-954D3D00-C643-4B79-8BB0-EDEA7C19FEE0Q33611308-088603E2-7CA0-418D-B425-844DD86037E9Q33615969-C40627F4-1CA2-49A5-AB74-BDB39B8F687AQ33621937-7F165052-8B7A-4004-8740-2369715331EAQ33640450-68713C48-72E1-4A1B-9A4D-E0957BB14391Q33645760-080762BC-C68D-4859-A48B-B4BFF39937E9Q33655100-03480670-8C59-46E3-A22A-93EB65C820DAQ33680270-73A53F07-8152-455C-AD18-E682997D1CBBQ33711691-2AEC6EFF-A587-427F-A6C3-D772BF9C8AA7Q33718822-49E27609-6EB4-40AF-88BB-69491657FD38Q33828580-C89C49BD-B8C7-4A3F-86CB-9F5DBF55FCC3Q34034180-BF67C914-DB27-42B5-8EA4-A48584B0C9F1Q34064049-BD060422-A515-4B76-A9F4-6DCA3CF709A2Q34095614-B31224A6-C71D-4BB1-8928-08058ADABF16Q34325815-19E21E57-9C13-4602-8983-439C4F95885DQ34350665-940B95F4-028C-4A14-8C67-B32FF08629EEQ34352879-AF07CA63-258A-4850-8771-88AEDEBA81D1Q34400424-06B9A109-43D7-4424-8134-6C999AA1C97BQ34463641-D8F8C86A-9D13-473A-B883-97FBE6515EACQ34568846-B384E095-1E71-42ED-9628-CFEA1F796DFBQ34570106-A9FFCC63-4A23-49C3-857D-88B8D224499EQ34610024-14C3FE33-202E-4710-85C8-CA9221EA71DBQ34644733-901E4433-7ED9-418B-8176-B1FB46C289D6
P2860
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Improved outcome for children ...... ber Consortium Protocol 91-01.
@ast
Improved outcome for children ...... ber Consortium Protocol 91-01.
@en
type
label
Improved outcome for children ...... ber Consortium Protocol 91-01.
@ast
Improved outcome for children ...... ber Consortium Protocol 91-01.
@en
prefLabel
Improved outcome for children ...... ber Consortium Protocol 91-01.
@ast
Improved outcome for children ...... ber Consortium Protocol 91-01.
@en
P2093
P356
P1433
P1476
Improved outcome for children ...... ber Consortium Protocol 91-01.
@en
P2093
Asselin BL
Clavell LA
Declerck L
Hurwitz CA
Moghrabi A
P304
P356
10.1182/BLOOD.V97.5.1211
P407
P577
2001-03-01T00:00:00Z